Online inquiry

IVTScrip™ mRNA-Anti-PD-L1&TGFBR2, M7824(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ10811MR)

This product GTTS-WQ10811MR is a type of mRNA modified with Pseudo-UTP, which ecodes the monoclonal antibody that targets PD-L1; TGFBR2 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001267706.2; NM_001024847.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 29126; 7048
UniProt ID Q9NZQ7; P37173
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PD-L1&TGFBR2, M7824(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ10811MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ10790MR IVTScrip™ mRNA-Anti-G, M777-16-3(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA M777-16-3
GTTS-WQ14391MR IVTScrip™ mRNA-Anti-IFNA1, RhuMAB IFNalpha(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA RhuMAB IFNalpha
GTTS-WQ13349MR IVTScrip™ mRNA-Anti-PDCD1, PF-06801591(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA PF-06801591
GTTS-WQ12631MR IVTScrip™ mRNA-Anti-ERBB2, OMNITARG™(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA OMNITARG™
GTTS-WQ8311MR IVTScrip™ mRNA-Anti-GLP1R, HM-12525A(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA HM-12525A
GTTS-WQ13819MR IVTScrip™ mRNA-Anti-S, REGN-10987(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA REGN-10987
GTTS-WQ9468MR IVTScrip™ mRNA-Anti-C5AR1, IPH-5401(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA IPH-5401
GTTS-WQ12398MR IVTScrip™ mRNA-Anti-CD3E, NI-0401(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA NI-0401
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW